Patent details

LUC00263 Product Name: anifrolumab

Basic Information

Publication number:
LUC00263
Type:
SPC
SPC Type:
Medical
Basic Patent Number:
EP097073969
Legal Status:
Inactive
Application number:
LUC00263
First applicant's nationality:
Procedural language:
English

Marketing Authorization

Marketing Authorization Number:
EU/1/21/1623
Marketing Authorization Type:
Marketing Authorization Date:
15/02/2022
Marketing Authorization Status:
Accepted
Marketing Authorization Country:
Luxembourg (LU)

Dates

Filing date:
18/05/2022
First Marketing Authorization date:
15/02/2022
Grant date:
25/04/2025
Activation date:
Publication date:
18/05/2022
Lapsed date:
Expiration date:
Renunciation date:
Revocation date:
Annulment date:
Basic SPC Expiration:
06/02/2034
SPC Extension Expiration:
06/02/2034
Rejection date:
Withdrawal date:

Owner

From:
18/05/2022
 
 

Name:
AstraZeneca AB
Address:
-, 151 85 Södertälje, Sweden (SE)

Agent

Name:
ARONOVA S.A.
From:
18/05/2022
Address:
PO Box 327, L-4004, ESCH-SUR-ALZETTE, Luxembourg (LU)
To:

Publication

Bulletin

1

Bulletin Heading:
SPC1
Bulletin edition number:
2022/07
Publication date:
03/06/2022
Description:
Section C : Published requests for Supplementary Protection Certificates – I1 publication

2

Bulletin Heading:
SPC2
Bulletin edition number:
2025/06
Publication date:
12/05/2025
Description:
Section D : Granted supplementary protection certificates – I2 publication

Annual Fees

Annual Fee Due Date:
28/02/2029
Annual Fee Number:
21
Annual Fee Amount:
410 Euro
Expected Payer:
Last Annual Fee Payment Date:
Last Annual Fee Paid Number:
Payer:
Filing date Document type Number of pages
18/05/2022 General Document 1
18/05/2022 Application Form 4
18/05/2022 Marketing authorization 3
18/05/2022 MA publication 10
18/05/2022 Marketing authorization 3
18/05/2022 Summary of the product caracteristics 29
18/05/2022 Outgoing Correspondence 1
18/05/2022 Publication 1
25/04/2025 Publication 1
25/04/2025 Certificate 1
25/04/2025 Outgoing Correspondence 1